Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cells of the Adaptive Immune Response

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immunogenicity of influenza split vaccine for 2025/26 season in Japan using a mouse model.

Japanese journal of infectious diseases·2026

Same author

Evaluation of Immunogenicity of Seasonal Influenza Split HA Vaccines Involved With Changes of Vaccine Strains Using Mouse and Human Sera.

Microbiology and immunology·2025

Same author

Variability in Single Radial Immunodiffusion (SRID) Potency Affected by Influenza Vaccine Reference Antigen/Antiserum Combinations: Relationship Between Dissociation Constant and Robustness of SRID Potency.

Japanese journal of infectious diseases·2025

Same author

Collaborative study on the cross-reactivity of two influenza B viral components in single radial immunodiffusion assay using quadrivalent influenza vaccines in Japan from 2015/16 to 2021-22 influenza season.

Biologicals : journal of the International Association of Biological Standardization·2024

Same author

Fratricide-resistant CD7-CAR T cells in T-ALL.

Nature medicine·2024

Same author

Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza vaccine viruses with appropriate antigenicity.

Vaccine·2024

Same journal

Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome.

Cytotherapy·2026

Same journal

Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Cytotherapy·2026

Same journal

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Cytotherapy·2026

Same journal

Overcoming five main challenges to targeting hematologic malignancies.

Cytotherapy·2026

Same journal

Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field.

Cytotherapy·2026

Same journal

Rethinking CAR-T manufacturing paradigms: terminology, operational considerations, and economic trade-offs.

Cytotherapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Manufacturing strategies for prolonged CAR-T cell persistence.

Noriko Shimasaki¹

¹Children's Cancer Center, Nagoya University Hospital, Nagoya, Aichi, Japan; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

|June 6, 2026

Summary

This summary is machine-generated.

Enhancing chimeric antigen receptor (CAR) T-cell therapy involves manufacturing strategies that enrich less-differentiated memory T cells. This approach improves CAR-T cell persistence and therapeutic efficacy for hematologic malignancies.

Keywords:

CAR-T cells differentiation exhaustion manufacturing memory T cells persistence

More Related Videos

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

Related Experiment Videos

Last Updated: Jun 8, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

Area of Science:

Immunotherapy
Cellular Therapy
Oncology

Background:

Chimeric antigen receptor (CAR) T-cell therapy shows promise for hematologic malignancies.
Limited CAR-T cell persistence due to exhaustion and loss hinders long-term efficacy.
Less-differentiated memory T cell subsets offer superior persistence and cytotoxicity.

Purpose of the Study:

To review current and emerging manufacturing strategies for CAR-T cells.
To focus on methods that enhance prolonged CAR-T cell persistence.
To explore personalized manufacturing for optimal CAR-T cell product composition.

Main Methods:

Enrichment of less-differentiated memory T cells during manufacturing.
Strategies include cell source selection and delayed differentiation.
Modulation of signaling pathways, epigenetics, and metabolism.

Main Results:

CAR-T cell products enriched for less-differentiated memory T cells demonstrate improved long-term persistence.
These products exhibit greater cytotoxicity and enhanced clinical outcomes.
Manufacturing strategies aim to optimize T cell differentiation states.

Conclusions:

Optimizing CAR-T cell manufacturing for enhanced persistence is crucial for sustained efficacy.
Further research is needed to determine ideal T cell compositions for specific clinical conditions.
Personalized CAR-T cell manufacturing can maximize therapeutic potential.